REPROCELL Corporate News

End of Q4 update from REPROCELL (2022-23)

Did you know that REPROCELL is celebrating its 20th anniversary this year? If you missed the commemorative letter from our CEO we have included a link below - plus everything else we’ve been up to since the start of 2023.

  1. Celebrating the 20th Anniversary of REPROCELL: A letter from our CEO Chika Yokoyama [LETTER]
  2. From rat aorta to resistance arteries: measuring vascular contractility [BLOG]
  3. Make a Difference with Fresh Residual Human Tissue Donation for Research – How to Get Involved! [BLOG]
  4. Everything you need to know about the motilin receptor [BLOG]
  5. Everything you need to know about the FDA Modernization Act 2.0 [BLOG]
  6. Clinical Trials: An Evolutionary Perspective [BLOG]
  7. Recombinant Human Laminins and their Use in Cell Culture [BLOG]

If you have any questions about our products and services, please reach out via our website - until then we wish you all the best for the new financial year.

Subscribe to receive updates from REPROCELL

Tagged

Life sciences

Stem cell and drug discovery scientists around the world are using REPROCELL’s services and products in their preclinical and clinical research.

 More about REPROCELL

REPROCELL Corporate News